Wells Fargo Raises Alnylam (ALNY) Revenue Estimates for Amvuttra Despite Projected Margin Compression

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best US stocks to buy and hold in 2026. On January 20, Wells Fargo adjusted its outlook on Alnylam Pharmaceuticals, lowering the price target to $376 from $479 while maintaining an Equal Weight rating. While the firm increased its 2026 revenue estimates for Amvuttra by 6%, it expressed concern over rising costs. Specifically, the firm expects R&D expenses to climb to ~30% of total revenue between 2026 and 2030. This reinvestment is projected to compress operating margins to roughly 30%.

On the same day, RBC Capital reduced its price target for Alnylam to $465 from $500 while maintaining an Outperform rating. This adjustment followed a meeting with the company’s management team to discuss the 2026 net product revenue outlook. Management addressed recent performance for Amvuttra, explaining that a soft November resulted from a few one-off factors, which were followed by an impressive December.

Earlier on January 12, Needham increased its price target for Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) from $520 to $529 with a Buy rating following the company’s Q4 2025 pre-announcement and the release of its 2026 financial outlook.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.

While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.